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Pemphigus and pemphigoid are autoimmune skin blistering diseas-
es. Pemphigoid is characterized by subepidermal blisters, inflamma-
tory cell infiltration, and the linear deposition of IgG autoantibod-
ies and complement components at the basement membrane zone 
(1). Bullous pemphigoid (BP) is by far the most common autoim-
mune subepidermal blistering disease. BP autoantibodies recognize 
2 hemidesmosomal components, BP180 and BP230 (1). BP230 (also 
referred to as BPAg1) is an intracellular protein that localizes to the 
hemidesmosomal plaque (2, 3). In contrast, BP180 (also referred to 
as BPAG2 or type XVII collagen) is a transmembrane protein (4, 5). 
The extracellular region of BP180 consists of 15 collagen domains 
separated from one another by non-collagen sequences. BP180-spe-
cific autoantibodies predominantly target epitopes located within 
the NC16A region of the ectodomain of the molecule (6, 7). Pem-
phigus is characterized by intraepidermal blisters and epidermis-spe-
cific autoantibodies (8). The 2 major forms of the disease are pem-
phigus foliaceus (PF) and pemphigus vulgaris (PV). In PF, blisters 
occur in the superficial epidermis (subcorneal blister), whereas in PV 
the epidermal cell separation occurs just above the basal layer of the 
epidermis (suprabasal blister). PF and PV autoantibodies recognize 
predominantly desmoglein 1 (Dsg1) and Dsg3, 2 transmembrane gly-
coproteins components of the desmosome, respectively (9). Reactiv-
ity of pemphigus autoantibodies with proteins other than Dsg1 and 
Dsg3 and the pathogenic potential of these autoantibodies have been 
documented (10–12). Pathogenicity of the anti-Dsg1, anti-Dsg3, and 
anti-BP180 antibodies has been demonstrated in IgG passive transfer 
mouse models. Neonatal mice injected with these pathogenic anti-
bodies develop PF-, PV-, and BP-like skin disease phenotypes, respec-
tively, at both clinical and histological levels (13–17). Subepidermal 
blistering in experimental BP depends on complement activation, 
mast cell degranulation, and neutrophil infiltration (18–20).
The conventional therapy for autoimmune diseases, including 
pemphigus and pemphigoid, has been high-dose, long-term system-
ic corticosteroids and immunosuppressive agents (21–23). However, 
long-term treatment with these drugs may cause many dose-related 
adverse effects (24). Intravenous Ig (IVIG) has been shown to be 
effective for the treatment of a variety of immune-mediated inflam-
matory diseases (25), including autoimmune cytopenias, Guillain-
Barré syndrome, multiple sclerosis, myasthenia gravis, anti–factor 
VIII autoimmune disease, dermatomyositis, Kawasaki disease, 
vasculitis, uveitis, and graft-versus-host disease (26–32). Recently, 
IVIG has also been reported to treat a small group of patients with 
human autoimmune blistering diseases, including pemphigus and 
pemphigoid (33, 34). However, the use of IVIG in these blistering 
diseases is still controversial, and no controlled study has been done 
on the efficacy of IVIG in the treatment of these diseases.
Numerous mechanisms have been proposed to explain the mode 
of action of IVIG, including regulation of functions of Fc recep-
tors, attenuation of complement-mediated tissue damage, neutral-
ization of autoantibodies by antiidiotypic antibodies, interference 
with the cytokine network, and modulation of effector functions 
of T and B cells (35–40) and/or the reticuloendothelial system (41). 
It has also been proposed that the beneficial action of IVIG in anti-
body-mediated disorders is due to its enhancement of IgG catabo-
lism, leading to an accelerated pathogenic autoantibody clearance 
Nonstandard	abbreviations	used: BP, bullous pemphigoid; Dsg1, desmoglein 1; 
FcRn, neonatal Fc receptor; HDIG, high-dose human IgG; IF, immunofluorescence; 
ITP, idiopathic thrombocytic purpura; IVIG, intravenous IgG; b2m, b2-microglobulin; 
mBP180, murine BP180 antigen; MPO, myeloperoxidase; PF, pemphigus foliaceus; 
PF1, PF patient 1; PV, pemphigus vulgaris; PV1, PV patient 1.
Conflict	of	interest: The authors have declared that no conflict of interest exists.
Citation	for	this	article: J. Clin. Invest. 115:3440–3450 (2005).  
doi:10.1172/JCI24394.
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 115   Number 12   December 2005 3441
(42–47). In experimental autoimmune idiopathic thrombocytic 
purpura (ITP) and the K/BxN mouse model of arthritis, IVIG has 
been suggested to protect against disease both by the saturation of 
the MHC-like class I Fc receptor and by recruitment of the inhibi-
tory Fc receptor FcγRIIb (47–50). Which mechanism(s) prevail in 
other autoantibody-mediated diseases remains to be determined.
FcγRIIb receptors are single-chain molecules bearing IgG-bind-
ing sites in their extracellular domains and cytoplasmic domains 
containing an immunoreceptor tyrosine inhibition motif. FcγRIIb 
deficiency is associated with increased susceptibility and sever-
ity to organ-specific and systemic autoimmune diseases, such as 
ITP, glomerulonephritis, arthritis, and lupus (51–54). Neonatal 
Fc receptor (FcRn) is a heterodimer of b2-microglobulin (b2m) 
and a 45-kDa α chain closely related to MHC class I (55). FcRn is 
expressed broadly, including in the placenta, intestine, and various 
vascular endothelia (56–58). It mediates the transport of maternal 
IgG across the placenta during gestation and across the intestine 
in neonates. FcRn is also responsible for the maintenance of serum 
IgG levels by binding and protecting IgG against lysosomal deg-
radation (57–64). Mice lacking b2m (b2m–/– mice) or the α chain 
(FcRn–/– mice) eliminate IgG several times faster than normal, 
resulting in reduced levels of circulating IgG (58, 62–65). Consis-
tent with rapid elimination of IgG, we previously showed that mice 
deficient in b2m, the light chain for all MHC class I family proteins, 
are resistant to experimental BP (66). In this study, we investigated 
potential mechanism(s) of IVIG action in antibody-mediated pem-
phigus and pemphigoid using mice deficient in the heavy chain of 
FcRn and FcγRIIb. Our studies show a striking example in which 
the therapeutic benefits of IVIG can be attributed to FcRn.
Results
High-dose human IgG treatment accelerates degradation of pathogenic anti–
murine BP180, anti-Dsg1, and anti-Dsg3 IgG and abolishes skin lesions. To 
better quantify the effect of high-dose human IgG (HDIG) on exper-
imental BP, PF, and PV, we first established an optimal dose for these 
pathogenic IgG preparations in neonatal mice, at which clear-cut 
clinical disease was present but pathogenic antibody was not used 
in excess. Mice were injected i.p. with different amounts of patho-
genic antibody and examined clinically 48 hours later. The optimal 
doses are listed in Table 1 and were used for all experiments in this 
study. In experimental BP, mice injected with pathogenic anti–
murine BP180 (anti-mBP180) IgG (25 µg/g body weight) developed 
typical BP skin lesions (subepidermal blisters) clinically (Figure 1A) 
and histologically (Figure 1B). In contrast, mice pretreated with 
HDIG and injected with an identical dose of pathogenic IgG showed 
a reduced disease phenotype, and the disease phenotype was com-
pletely abolished at higher doses (Figure 1, C–G). A dose of 0.5 mg/g 
body weight HDIG reduced skin clinical disease score from 1.68+ 
down to 0, with a minimal degree of microscopic dermal-epider-
mal separation (Figure 1, C and D). Treatment with 1 and 2 mg 
HDIG completely blocked pathogenic activity of anti-mBP180 IgG 
(Figure 1, E–G). The severity of BP skin blistering is directly corre-
lated to number of infiltrating neutrophils (19). Quantification of 
neutrophil infiltration by the neutrophil cell marker myeloperoxi-
dase (MPO) assay showed significant reduction in the enzyme activ-
ity at the injection site in the HDIG-treated mice compared with dis-
eased mice (Figure 1H). ELISA assay revealed a significant reduction 
in circulating pathogenic anti-mBP180 IgG levels in HDIG-treated 
mice compared with diseased mice (Figure 1I). As a control, mice 
pretreated with the same dose of IgM as HDIG showed similar levels 
of serum anti-mBP180 IgG and the same degree of clinical disease as 
compared with the diseased mice (Figure 1 and Table 2).
In experimental PF, anti-Dsg1 antibody (40 and 50 µg/g body 
weight for PF patient 1 [PF1] and PF2, respectively) induced subcor-
neal blisters, a hallmark of PF in mice (Figure 2, A and B and Table 2). 
In contrast, mice pretreated with HDIG followed by the same 
dose of pathogenic IgG failed to develop skin lesions (Figure 2, 
C and D). Pathogenic anti-Dsg1 IgG levels in circulation in the 
HDIG-treated mice were significantly reduced (Figure 2E). Similarly, 
in experimental PV, anti-Dsg3 antibody (50 and 60 µg/g body weight 
for PV patient 1 [PV1] and PV2, respectively) induced suprabasal 
blisters, a hallmark of PV in mice (Figure 2, F and G and Table 2). 
In contrast, mice pretreated with HDIG followed by the same dose of 
pathogenic IgG failed to developed skin lesions (Figure 2, H and I). 
Pathogenic anti-Dsg3 IgG levels in circulation in the HDIG-treated 
mice were significantly reduced (Figure 2J). As a control, mice pre-
treated with the same dose of IgM as HDIG showed similar degrees 
of clinical disease as compared with the diseased PF and PV mice 
(Figure 2 and Table 2). These results are consistent with the hypoth-
esis that HDIG treatment prevents antibody-induced blister forma-
tion by increasing pathogenic IgG degradation.
This hypothesis predicts an increased catabolism of total rabbit 
IgG (for the BP model) and human autoantibody IgG (for the PF and 
PV models) in the HDIG-treated mice. The next set of experiments 
proved this was the case. Rabbit IgG-specific and anti-mBP180–spe-
Table 1
Optimal doses of anti-mBP180, anti-Dsg1, and anti-Dsg3  
in miceA
Antibody	 IgG	dose		 No.	of		 Clinical
	 (µg/g		 mice	 disease	score
	 body	weight)	 	 (mean	±	SEM)
Anti-mBP180 50 4 2.88 ± 0.10
 25B 4 1.63 ± 0.13
 12.5 4 0.63 ± 0.13
 6.25 4 0.00 ± 0.00
Anti-Dsg1 (PF1) 100 4 3.00 ± 0.00
 50 4 2.25 ± 0.14
 40B 4 1.38 ± 0.13
 25 4 0.25 ± 0.14
Anti-Dsg1 (PF2) 100 4 2.50 ± 0.20
 50B 4 1.38 ± 0.13
 40 4 0.50 ± 0.00
 25 4 0.00 ± 0.00
Anti-Dsg3 (PV1) 100 4 2.88 ± 0.13
 60 4 1.88 ± 0.13
 50B 4 1.38 ± 0.13
 25 4 0.00 ± 0.00
Anti-Dsg3 (PV2) 100 4 1.75 ± 0.14
 60B 4 1.25 ± 0.14
 50 4 0.75 ± 0.14
 25 4 0.00 ± 0.00
ANeonatal WT mice were injected i.p. with pathogenic anti-mBP180, 
anti-Dsg1, or anti-Dsg3 IgG (µg/g body weight). Injected animals were 
examined clinically 48 hours after IgG injection, and disease activity 
was scored, averaged in each group, and expressed as mean disease 
score ± SEM (see Methods for more details). There was a significant 
difference in clinical disease scores between mice with blisters and mice 
without blisters (P < 0.0001). BOptimal dose of pathogenic IgG, which 
induces clinical blisters and gives the most sensitive dose response.
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cific ELISA assays showed similar decreases in total and antigen-
specific rabbit IgG levels in the HDIG-treated mice: decreases in 
relative OD reading for total rabbit IgG versus the relative OD read-
ing for mBP180-specific rabbit IgG at different HDIG doses were 
0.98 ± 0.11 versus 0.73 ± 0.21 (0.5 mg HDIG; P = 0.32), 1.37 ± 0.19 
versus 1.34 ± 0.14 (1 mg HDIG; P = 0.89), and 1.68 ± 0.11 versus 
1.50 ± 0.18 (2 mg HDIG; P = 0.39). The rate of increased catabolism 
(expressed as percent decrease) of total rabbit IgG and anti-mBP180 
IgG in the HDIG-treated mice was also very similar: percent decreas-
es in total IgG versus mBP180-specific IgG were 42% versus 32% 
(0.5 mg HDIG; P = 0.22), 59% versus 61% (1.0 mg HDIG; P = 0.57), 
and 73% versus 68% (2.0 mg HDIG; P = 0.39). Since PF and PV 
autoantibodies used in these experiments were antigen specific, we 
expected that as in the BP model, changes in total PF and PV IgG lev-
els versus Dsg1- and Dsg3-specific IgG levels should be the same.
This hypothesis also predicts that HDIG will no longer inhibit the 
disease activity when the pathogenic antibodies are used at higher 
levels than the threshold level for the disease development. To prove 
this, mice were pretreated with IgM control (6.47 mg/g body weight) 
or HDIG (1 mg/g body weight), injected with different doses of 
pathogenic anti-mBP180 antibodies (25, 50, 100, and 200 µg/g body 
weight), and examined clinically at 48 hours. A dose of 1 mg/g body 
weight of HDIG completely abolished BP disease in mice injected 
with 25 µg/g body weight of anti-mBP180 antibody. As patho-
genic antibody levels were increased, the inhibition activity of the 
1 mg HDIG was gradually diminished: the disease activities in the 
IgM- versus HDIG-treated mice were 2.92 ± 0.08 versus 1.25 ± 0.11 
(50 µg; P < 0.0001), 3 ± 0.00 versus 2.83 ± 0.11 (100 µg; P = 0.14), 
and 3 ± 0.00 versus 3 ± 0.00 (200 µg; P = 1.00).
FcRn-deficient mice are resistant to experimental BP, PF, and PV. If the 
function of HDIG is to increase pathogenic antibody degradation, 
then mice deficient in FcRn should phenocopy HDIG-treated WT 
mice. Our next set of experiments proved this is the case. As shown 
previously (66), pathogenic anti-mBP180 IgG (25 µg/g body weight) 
induced BP disease in WT (Figure 3, A and C) but not FcRn–/– mice 
(Figure 3, D and F). The non-diseased FcRn–/– mice showed signifi-
cantly reduced levels of neutrophil recruitment in the skin (Figure 3G) 
and pathogenic IgG in circulation (Figure 3H) as compared with 
the diseased mice (n = 9 for each group). Total rabbit IgG levels were 
also significantly reduced in the FcRn–/– mice (2.09 ± 0.31 down to 
0.86 ± 0.10; P < 0.001). The reduced IgG level in the circulation also 
led to a marked reduction in in situ deposition of anti-mBP180 IgG 
at the basement membrane, as assayed by direct immunofluorescence 
(IF) (Figure 3, B vs. E). Similarly, pathogenic anti-Dsg1 (Figure 4, A–C) 
and anti-Dsg3 (Figure 4, D–F) IgG failed to trigger PF and PV skin 
lesions in FcRn–/– mice (n = 6), respectively, with significantly reduced 
Figure 1
High-dose Ig inhibits experimental BP by accelerating degradation of pathogenic anti-mBP180 IgG. Neonatal C57BL/6J mice were pretreated 
with buffer, IgM (12.93 mg/g body weight), or different doses of HDIG (0–2 mg/g body weight) and injected i.p. with pathogenic IgG (25 µg/g body 
weight) 2 hours later. The animals were examined 48 hours after pathogenic IgG injection. Control mice showed typical BP clinically (A) and 
histologically (B). In contrast, mice pretreated with HDIG were protected from BP, and the protective effect was dose dependent (C–F). (G) HDIG 
treatment resulted in significant reduction in clinical skin disease (bars 3–5) as compared with IgM (bar 1) and buffer controls (bar 2). (H) MPO 
assays revealed a significant reduction in neutrophil infiltration in mice treated with HDIG (bars 3–5) as compared with control mice (bars 1 and 2). 
(I) ELISA showed a similar pattern of reduction in circulating pathogenic IgG in mice treated with HDIG (bars 3–5) relative to controls (bars 1 and 2). 
n = 8 in each group. *P < 0.05; **P < 0.001. e, epidermis; d, dermis; v, vesicle. Arrow indicates site of pathogenic antibody binding.
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levels of pathogenic antibody in circulation. These data show that 
FcRn deficiency and HDIG treatment lead to the same degree of 
accelerated degradation of pathogenic IgG.
Increased pathogenic IgG degradation by HDIG is mediated by FcRn. If 
HDIG acts on FcRn to accelerate pathogenic IgG degradation, then 
HDIG will not effect pathogenic IgG degradation in FcRn–/– mice. 
To test this, we injected pathogenic IgG i.p. into FcRn-deficient 
mice pretreated with IgM control or HDIG and monitored circu-
lating pathogenic IgG levels at different time points (6–48 hours). 
As expected, WT mice injected with pathogenic anti-mBP180 IgG 
(25 µg/g body weight) without HDIG pretreatment maintained high 
levels of circulating pathogenic IgG across all time points and devel-
oped subepidermal blisters at 24 and 48 hours (Figure 5A). In con-
trast, FcRn–/– mice injected with pathogenic anti-mBP180 IgG and 
WT mice coinjected with pathogenic IgG and HDIG (1 mg/g body 
weight) exhibited a significant reduction in circulating pathogenic 
IgG and failed to developed BP lesions (Figure 5A). However, admin-
istration of the same dose or a 2-fold higher dose of HDIG failed 
to induce further degradation of pathogenic IgG in FcRn-deficient 
mice compared with FcRn-deficient mice without HDIG treatment 
(Figure 5A). Similar patterns were also observed in experimental PF 
and PV: HDIG failed to increase the clearance of anti-Dsg1 and anti-
Dsg3 IgG in FcRn–/– mice (Figure 5, B and C). The ability of HDIG 
but not IgM to promote the clearance of pathogenic IgG in WT but 
not FcRn–/– mice and to mirror the clearance observed in FcRn–/– 
mice is consistent with HDIG recapitulating the FcRn–/– phenotype 
by saturating the FcRn protection pathway.
We also determined whether HDIG offered some additional 
effect when FcRn–/– mice were injected with higher doses of patho-
genic IgG. FcRn–/– mice were pretreated with buffer, control IgM, 
or HDIG and 2 hours later were injected i.p. with 2- and 4-fold 
more pathogenic anti-mBP180 (50 and 100 µg/g body weight), 
anti-Dsg1 (80 and 160 µg/g body weight), or anti-Dsg3 (100 and 
200 µg/g body weight) IgG. The mice were examined 48 hours 
after pathogenic IgG injection. As expected, the mice developed 
skin lesions in a dose-dependent fashion (Figure 6, A and B). High-
er doses of pathogenic IgG caused more severe clinical blistering. 
However, there was no statistically significant difference in patho-
genic IgG levels between FcRn–/– mice with and without HDIG 
pretreatment at these pathogenic IgG doses (Figure 6, A and B). 
Higher doses of pathogenic IgG resulted in lower IgG degradation 
rates (Figure 6, C–E). These results suggest that FcRn is required in 
order for HDIG to promote the clearance of pathogenic IgG.
FcRn deficiency and HDIG treatment do not interfere with the direct binding 
of pathogenic IgG to its target. To determine whether the lack of FcRn and 
HDIG treatment interferes with pathogenic IgG binding to its target 
that leads to inhibition of blistering, pathogenic IgG was mixed with 
buffer control, IgM control, or HDIG at final concentrations similar 
to or higher than the therapeutic serum level of HDIG in the mouse 
model (pathogenic IgG/HDIG or IgG/IgM were mixed at a 1:25 
molar ratio). The preabsorbed pathogenic IgG was then tested for 
antigen binding and pathogenic activities. In vitro, we stained skin 
sections from WT and FcRn–/– mice with serial dilutions up to the 
detection limits for the positive samples without HDIG preabsorp-
tion (anti-mBP180, 1:1,000 to 1:8,000 dilutions; anti-Dsg1, 1:200 to 
1:800 dilutions; and anti-Dsg3, 1:200 to 1:800 dilutions). There was 
no detectable difference in indirect IF staining density between WT 
and FcRn–/– skin sections and no detectable difference in staining 
density with and without HDIG coincubation (Figure 7, A–C).
In vivo, WT and FcRn–/– mice injected intradermally with patho-
genic anti-mBP180, anti-Dsg1, or anti-Dsg3 IgG preabsorbed with 
buffer, IgM, or HDIG developed clinical BP, PF, and PV, respectively 
(Figure 7D and Table 2). As expected, the disease activity in WT mice 
injected with HDIG-preabsorbed pathogenic antibody was very sim-
ilar to that in WT mice injected with buffer- or IgM-preabsorbed 
pathogenic antibody. Pathogenic IgG levels in WT mice injected 
with HDIG-preabsorbed pathogenic antibody were lower than 
in WT mice injected with IgM-preabsorbed pathogenic antibody 
(Figure 7E). There was no difference in clinical disease scores and 
serum IgG levels between WT mice injected with buffer- and IgM-
preabsorbed pathogenic antibody (Figure 7, D and E). FcRn–/– mice 
injected with buffer-, IgM- and HDIG-preabsorbed pathogenic IgG 
had compatible levels of circulating pathogenic IgG and developed 
clinical blisters to the same degree (Table 2). Similar results were 
Table 2
Relative contribution of FcRn and FcγRII pathways to experimen-
tal pemphigus and pemphigoidA
Mouse		 Antibody	 No.	of	 Clinical		 P	
strain	 	 mice	 disease	score		 value
	 	 	 (mean	±	SEM)
WT Anti-mBP180 6 1.67 ± 0.11 –
 Anti-mBP180 + IgM 6 1.75 ± 0.27 0.5994
 Anti-mBP180 + HDIG 6 0.00 ± 0.00 0.0001
FcRn–/– Anti-mBP180 6 0.08 ± 0.08 0.0001
 Anti-mBP180 + IgM 6 0.00 ± 0.00 0.0001
 Anti-mBP180 + HDIG 6 0.00 ± 0.00 0.0001
 Anti-mBP180 (i.d.) + HDIG 6 2.08 ± 0.15 0.0493
FcγRII–/– Anti-mBP180 6 1.83 ± 0.11 0.3632
 Anti-mBP180 + IgM 6 1.75 ± 0.11 0.5995
 Anti-mBP180 + HDIG 6 0.17 ± 0.11 0.0004
WT Anti-Dsg1 6 1.50 ± 0.13 –
 Anti-Dsg1 + IgM 6 1.83 ± 0.11 0.0734
 Anti-Dsg1 + HDIG 6 0.00 ± 0.00 0.0001
FcRn–/– Anti-Dsg1 6 0.08 ± 0.08 0.0003
 Anti-Dsg1 + IgM 6 0.00 ± 0.00 0.0001
 Anti-Dsg1 + HDIG 6 0.08 ± 0.08 0.0001
 Anti-Dsg1 (i.d.) + HDIG 6 1.75 ± 0.11 0.1739
FcγRII–/– Anti-Dsg1 6 1.42 ± 0.13 0.6951
 Anti-Dsg1 + IgM 6 1.42 ± 0.15 0.6867
 Anti-Dsg1 + HDIG 6 0.17 ± 0.11 0.0005
WT Anti-Dsg3 6 1.58 ± 0.15 –
 Anti-Dsg3 + IgM 6 1.75 ± 0.17 0.4848
 Anti-Dsg3 + HDIG 6 0.08 ± 0.08 0.0001
FcRn–/– Anti-Dsg3 6 0.08 ± 0.08 0.0004
 Anti-Dsg3 + IgM 6 0.08 ± 0.08 0.0001
 Anti-Dsg3 + HDIG 6 0.08 ± 0.08 0.0001
 Anti-Dsg3 (i.d.) + HDIG 6 1.83 ± 0.11 0.2094
FcγRII–/– Anti-Dsg3 6 1.50 ± 0.13 0.7412
 Anti-Dsg3 + IgM 6 1.75 ± 0.21 0.5413
 Anti-Dsg3 + HDIG 6 0.00 ± 0.00 0.0001
ANeonatal mice were pretreated with buffer, IgM control (6.47 mg/g 
body weight), or HDIG (1 mg/g body weight) and 2 hours later injected 
i.p. with optimal dose of antigen-specific column-purified anti-mBP180 
(25 µg/g body weight), anti-Dsg1 (PF1, 40 µg/g body weight), or anti-
Dsg3 IgG (50 µg/g body weight). Injected animals were examined clini-
cally 48 hours after pathogenic IgG injection, and clinical disease activ-
ity was scored and averaged in each group and expressed as mean 
disease score ± SEM (see Methods for more details). P values between 
positive control group and deficient mouse groups were calculated by 
paired Student’s t test. A P value less than 0.05 was considered signifi-
cant. i.d., intradermal.
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seen in mice injected i.p. with HDIG first followed by intradermal 
injection of pathogenic antibody (data not shown). These results 
demonstrate that the HDIG preparation used in this study does not 
contain antibodies that inhibit binding of pathogenic anti-BP180, 
anti-Dsg1, and anti-Dsg3 to respective target antigens in skin.
FcγRIIb is not required for the antiinflammatory activity of HDIG and does 
not ameliorate skin lesions in experimental BP, PF, and PV. The inhibitory 
FcγRII receptor is considered to be a target for IVIG action in the 
autoimmune ITP and K/BxN arthritis models (48–50). To assess the 
contribution of FcγRII to HDIG activity in our pemphigus and pem-
Figure 2
HDIG inhibits experimental PF and PV 
by accelerating degradation of patho-
genic human autoantibody IgG. Neona-
tal C57BL/6J mice were pretreated with 
buffer, IgM (12.93 mg/g body weight), or 
different doses of HDIG (0–2 mg/g body 
weight) and injected i.p. with pathogenic 
anti-Dsg1 IgG (PF1, 40 µg/g body weight) 
or anti-Dsg3 IgG (PV1, 50 µg/g body 
weight) 2 hours later. The animals were 
examined 48 hours after pathogenic IgG 
injection. Mice without HDIG treatment 
developed subcorneal PF blisters (A and 
B), while 1 mg HDIG completely blocked 
skin lesions (C and D). (E) HDIG treat-
ment resulted in significant reduction in 
clinical disease scores and levels of cir-
culating anti-Dsg1 IgG (bars 3–5) as com-
pared with control (bars 1 and 2). Mice 
without HDIG treatment developed supra-
basal PV blisters (F and G), while 1 mg 
HDIG completely blocked skin lesions 
(H and I). (J) HDIG treatment resulted in 
significant reduction in clinical disease 
scores and levels of circulating anti-Dsg3 
IgG (bars 3–5) relative to control (bars 
1 and 2). n = 8. *P < 0.05; **P < 0.001. 
Arrows indicate basal keratinocytes.
Figure 3
FcRn-deficient mice are resistant to experimental BP. Neonatal WT and FcRn–/– mice were injected i.p. with pathogenic anti-mBP180 IgG or 
normal rabbit IgG control (25 µg/g body weight) and examined 48 hours after injection. WT mice receiving pathogenic IgG developed clinical (A) 
and histological (C) evidence of subepidermal blisters. Direct IF exhibited in vivo deposition of rabbit anti-mBP180 IgG at the basement mem-
brane (B). In contrast, FcRn–/– mice showed no skin lesions (D and F) and very weak IgG deposition at the basement membrane (E). (G) The 
MPO assay showed a significant reduction in neutrophil infiltration in FcRn–/– mice relative to WT mice. (H) ELISA assay revealed a significant 
acceleration of pathogenic IgG degradation in FcRn–/– mice. n = 6. *P < 0.01. Arrow indicates site of pathogenic antibody binding.
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phigoid models, we injected WT and FcγRII–/– mice with pathogenic 
anti-mBP180, anti-Dsg1, and anti-Dsg3 antibodies in the presence or 
absence of HDIG treatment. At 48 hours after injection, these mice 
were examined clinically, and levels of circulating pathogenic anti-
bodies were quantified by ELISA. FcγRII–/– mice injected with patho-
genic IgG developed a similar intensity of skin lesions compared with 
diseased WT mice, and there was no difference in levels of pathogenic 
IgG between these 2 groups (Figure 8 and Table 2). HDIG treatments 
(1 mg/g body weight) but not IgM control 
blocked skin blistering and caused a very 
similar degree of reduction in pathogenic 
IgG levels in the circulation in WT and 
FcγRII–/– mice (Figure 8). These results dem-
onstrate that the antiinflammatory activ-
ity of HDIG in the BP, PF, and PV mouse 
models, under the experimental conditions 
used, is not dependent on FcγRII.
Discussion
Despite its increasing applications in the 
treatment of immune-mediated inflam-
matory diseases, the mechanism(s) of IVIG 
action remain unclear. Using IgG passive 
transfer models of autoimmune blistering 
diseases pemphigus and pemphigoid, we 
show that FcRn is absolutely required to 
realize a benefit from HDIG therapy. Our 
data show that (a) mice deficient in FcRn 
are resistant to experimental pemphigus 
and pemphigoid and show a substantial 
reduction in circulating pathogenic IgG 
antibodies; (b) similar to an FcRn deficiency, 
HDIG treatment causes accelerated clear-
ance of pathogenic antibody and abolishes 
skin lesions; (c) HDIG treatment of FcRn-
deficient mice fails to cause a further low-
ering of pathogenic antibody. These results 
are in agreement with findings in ITP and 
serum-induced arthritis models, all sug-
gesting that a high dose of IVIG saturates 
FcRn binding sites and hence pathogenic 
antibodies lose FcRn protection and are more rapidly degraded. The 
faster degradation prevents pathogenic antibody from reaching its 
tissue targets in the skin, and skin blistering is abolished.
Our findings demonstrate a common mechanism for HDIG 
activity in 3 models for antibody-mediated skin blistering disease. 
Subcorneal blistering in PF and suprabasal blistering in PV are 
triggered by binding of pathogenic anti-Dsg1 and anti-Dsg3 IgG 
to their skin targets, and complement activation is not required 
Figure 4
FcRn-deficient mice are resistant to experimen-
tal PF and PV. Neonatal WT and FcRn–/– mice 
were injected i.p. with pathogenic anti-Dsg1 
(PF1, 40 µg/g body weight) (A–C) or anti-Dsg3 
(PV1, 50 µg/g body weight) (D–F) IgG and 
examined 48 hours after injection. (A–C) PF 
model. WT mice receiving pathogenic IgG devel-
oped subcorneal blisters (A), while FcRn–/– mice 
showed no skin lesions (B). (C) ELISA revealed 
a significant reduction in circulating anti-Dsg1 
IgG levels in FcRn–/– as compared with WT 
mice. (D–F) PV model. WT mice receiving 
pathogenic IgG developed suprabasal blisters 
(D), while FcRn–/– mice showed no skin lesions 
(E). (F) ELISA revealed a significant reduction 
in circulating anti-Dsg3 IgG levels in FcRn–/– as 
compared with WT mice. n = 8. *P < 0.01. 
Arrow indicates basal keratinocytes.
Figure 5
No further degradation of pathogenic IgG by HDIG in FcRn-deficient mice. WT and FcRn–/– mice 
were pretreated with buffer control, IgM control (6.47 mg/g body weight), or HDIG (1 mg/g body 
weight) and then injected i.p. with pathogenic anti-BP180 IgG (25 µg/g body weight), anti-Dsg1 
IgG (PF1, 40 µg/g body weight), or anti-Dsg3 IgG (50 µg/g body weight). Pathogenic IgG levels 
in circulation at different time points after pathogenic IgG injection were quantified by ELISA. 
(A) BP model. Significantly higher levels of circulating anti-BP180 IgG were present in WT mice 
without HDIG treatment than WT mice with HDIG treatment at 12, 24, and 48 hours. In contrast 
to WT mice, FcRn-deficient mice with and without HDIG treatment showed similar levels of cir-
culating anti-BP180 IgG. IgM pretreatment had no effect on the serum anti-mBP180 IgG levels at 
all time points examined (1.04 ± 0.11, 2.47 ± 0.34, 2.09 ± 0.32, and 2.16 ± 0.29 OD492nm reading 
units at 6, 12, 24, and 48 hours, respectively). (B) PF model. HDIG treatment resulted in signifi-
cantly reduced levels of anti-Dsg1 IgG in WT mice but not in FcRn–/– mice 48 hours after injection 
as compared with control IgM-treated WT mice. (C) PV model. As in the PF model, HDIG caused 
a significant reduction in circulating anti-Dsg3 IgG levels in WT but not in FcRn–/– mice 48 hours 
after injection. These data show that increased degradation of pathogenic IgG is mainly depen-
dent upon the FcRn-mediated pathway. n = 6. *P < 0.05; **P < 0.001.
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(8). Subepidermal blistering in BP is induced by pathogenic anti-
BP180 IgG and depends on complement activation, mast cell 
degranulation, and neutrophil infiltration (18–20). However, 
HDIG treatment led to a similar degree of reduction in circulating 
pathogenic antibodies in all 3 blistering disease models regardless 
of their disease mechanisms. These findings should be directly 
beneficial to other human blistering diseases in which IgG autoan-
tibodies target Dsg3 and BP180, including paraneoplastic pemphi-
gus (anti-Dsg3) (67), mucous membrane pemphigoid, pemphigoid 
gestationis, lichen planus pemphigoides (anti-BP180) (68–70).
The ratio of HDIG to anti-mBP180 IgG in mice was 1 mg HDIG/g 
body weight versus 1:1,280 anti-mBP180 IgG titer. In PF and PV 
mice, the HDIG/anti-Dsg1 or HDIG/anti-Dsg3 IgG ratio was 1 mg 
HDIG/g body weight versus 1:640 anti-Dsg1 or anti-Dsg3 IgG titer. 
In IVIG-treated patients (BP, PF, and PV), the IVIG/patients’ autoan-
tibody ratio is approximately 0.7 g IVIG/kg body weight/day/3-day 
cycle versus 1:160 (1:40 to 1:640 for most patients’ sera) autoanti-
body titers (34). The ratio of IVIG levels/autoantibody levels in the 
serum of treated patients is compatible with that of the treated mice. 
However, mice received only 1 dose of patho-
genic IgG, while pathogenic autoantibodies 
are constantly synthesized in patients. There-
fore, higher levels (higher dose and/or multiple 
doses) of IVIG should be recommended for 
treating these patients. Our findings also sug-
gest that IVIG will only work through FcRn in 
patients with antibody concentrations below 
that which results in FcRn saturation, as sug-
gested in the arthritis model (50).
The extent to which the therapeutic benefits 
of HDIG in the autoimmune blistering dis-
ease PF, PV, and BP models are dependent on 
FcRn is intriguing. We ruled out the possibility 
that HDIG used in our study contains antiid-
iotypic antibodies that neutralize anti-Dsg1, 
anti-Dsg3, and anti-BP180 IgG because up to a 
25-fold excess HDIG still shows no blocking of 
pathogenic antibody binding to the respective 
targets in the skin and inducing skin lesions 
(Figure 7). In experimental immune ITP and 
in the K/BxN murine model of autoimmune 
arthritis, IVIG has been shown to act through 
both the FcRn saturation and the FcγRII 
inhibitory pathways (48–50). Recent studies 
performed using the ITP and K/BxN serum 
transfer models have additionally shown an 
FcγRII-dependent pathway in which natural 
autoantibodies forming soluble antigen anti-
body complexes are antiinflammatory (71). 
However, in experimental antiphospholipid 
antibody syndrome, IVIG ameliorates the dis-
ease in a manner inconsistent with proinflam-
matory FcγR involvement, possibly by FcRn 
saturation, but a role for FcγRII has not been 
formally excluded (45). Our findings suggest 
that FcRn saturation is a dominant mecha-
nism for the action of HDIG in the pemphigus 
and pemphigoid models. While various mech-
anisms could operate additively or synergisti-
cally depending on the modeled disease, the 
common, emerging theme is that the FcRn saturation pathway is 
invoked by HDIG in all autoimmune models induced by pathogenic 
IgG antibodies analyzed to date. This is logical, as FcRn controls 
the availability of autoantibodies available for whatever downstream 
events mediate the particular disease’s pathological processes.
It is also of interest that FcγRIIb–/– mice showed the same degree 
of the BP disease as did the WT mice (Table 2). The inhibitory IgG 
receptor FcγRIIb is expressed on leukocytes including B cells, mac-
rophages, neutrophils, and mast cells and downregulates functions 
of the activating IgG receptors FcγRI and -RIII. Mice deficient in 
FcγRIIb develop more severe autoimmune diseases, such as ITP, glo-
merulonephritis, arthritis, and lupus (51–54). Neutrophils and mast 
cells are absolutely required for subepidermal blistering in experi-
mental BP (19, 20), Our findings that mice deficient in FcγRIIb fail 
to develop more intense skin lesions is therefore inconsistent with a 
normal antiinflammatory role for FcγRIIb in this disease.
In summary, the HDIG activity in the treatment of IgG anti-
body-induced pemphigus and pemphigoid in mice is mainly 
dependent on FcRn. Overall, IVIG is not an ideal antiautoim-
Figure 6
Relationship among pathogenic IgG doses, IgG clearance rate, and disease activity in FcRn-
deficient mice. (A and B) FcRn–/– mice were pretreated with IgM (6.47 mg/g body weight) or 
HDIG (1 mg/g body weight) and 2 hours later injected i.p. with different doses of anti-mBP180 
R530, anti-Dsg1 (PF1), or anti-Dsg3 (PV1). The mice were examined 48 hours after pathogenic 
IgG injection. Serum anti-mBP180 IgG levels in mice pretreated with IgM (black bars) or HDIG 
(white bars) were quantified by ELISA. Disease activities in mice pretreated with IgM (dark gray 
bars) or HDIG (light gray bars) were scored by clinical examination. As expected, higher doses 
of anti-mBP180 IgG (A), anti-Dsg1 IgG (B), and anti-Dsg3 IgG (data not shown) caused higher 
levels of pathogenic IgG in circulation and more severe clinical diseases. There was no differ-
ence in IgG levels and disease severity between IgM- and HDIG-treated mice at each dose of 
pathogenic IgG. (C–E) WT and FcRn–/– mice were injected i.p. with different doses of patho-
genic IgG, and serum pathogenic IgG levels were assayed by ELISA 48 hours later. 59.1%, 
50.6%, and 35.3% decreases (decr.) in anti-mBP180 IgG levels were seen in FcRn–/– compared 
with WT mice at 25, 50, and 100 doses, respectively (C). Similarly, higher doses of anti-Dsg1 
and anti-Dsg3 IgG led to lower rates of IgG degradation (D and E). n = 6.
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mune therapeutic because of its expense, extended course of 
delivery, and side effects. It is thus usually reserved for patients 
that are nonresponsive to other therapies. Selective blockade of 
FcRn is, therefore, a promising generic therapeutic strategy.
Methods
Animals. Breeding pairs of FcRn–/– mice on a C57BL/6J background (65) 
and WT C57BL/6J mice were obtained from the Jackson Laboratory. 
FcγRIIb–/– mice on a C57BL/6J background were obtained from Tacon-
ic. The animals were bred at the University of North Carolina at Chapel 
Hill Animal Resource Center. Neonatal mice (36–48 hours old with body 
weights between 1.5 and 1.8 g) were used for passive transfer experiments. 
Animal care and animal experiments were approved by the Animal Care 
Committee at the University of North Carolina at Chapel Hill and were in 
accordance with NIH guidelines.
Affinity-purification of pathogenic anti-Dsg1, anti-Dsg3, and anti-BP180 IgG. 
Anti-Dsg1 and anti-Dsg3 autoantibodies were affinity-purified from PF 
(n = 2, PF1 and PF2) and PV (n = 2, PV1 and PV2) patients, respectively, 
using the entire extracellular domain of Dsg1 and Dsg3 produced by the 
baculovirus system immobilized with Ni-NTA columns (QIAGEN) (72). 
The preparation of recombinant mBP180 and the immunization of rab-
bits were performed as previously described (14). Briefly, a segment of the 
mBP180 antigen containing the pathogenic epitope was expressed, purified 
to homogeneity by affinity chromatography, and used to immunize New 
Zealand White rabbits. The IgG fraction from the sera (referred to as R530) 
was isolated as previously described (17), and pathogenic anti-mBP180 IgG 
was further purified using the recombinant mBP180 fragment containing 
pathogenic epitope (73) immobilized in an agarose affinity column. The 
titer of purified antibodies was assayed by indirect IF using mouse skin 
cryosections as substrate (17). The pathogenicity of the purified IgG was 
tested by passive transfer experiments as described below.
Induction of experimental BP, PF, and PV. A 50-µl dose of sterile IgG in PBS 
was administered to neonatal mice by i.p. injection (0–100 µg IgG/g body 
weight). The skin of neonatal mice from the test and control groups was 
examined at 24 and 48 hours after the IgG injection. The extent of cutaneous 
disease for IgG passive transfer BP was scored as follows: –, no detectable skin 
Figure 7
HDIG does not directly inhibit activities of pathogenic IgG. Pathogenic IgG (1 mg/ml R530, anti-Dsg1 from PF1, or anti-Dsg3 from PV1) was incu-
bated with buffer control, IgM, or HDIG (25 mg/ml) at room temperature for 1 hour. (A) Supernatants containing anti-mBP180 IgG coincubated with 
buffer or HDIG showed the same IF staining density at the basement membrane zone. Supernatants containing anti-Dsg1 (B) or anti-Dsg3 (C) 
IgG coincubated with buffer or HDIG showed the same IF staining density at the keratinocyte cell surface. Supernatants with IgM preabsorption 
showed the same IF density (data not shown). (D) Supernatants containing anti-mBP180 (equivalent to 25 µg/g body weight), anti-Dsg1 (equiva-
lent to 40 µg/g body weight), or anti-Dsg3 (equivalent to 50 µg/g body weight) preabsorbed with buffer (bars 1, 3, and 7), IgM (bars 2, 5, and 8), or 
HDIG (bars 3, 6, and 9), when injected intradermally into WT or FcRn–/– mice (Table 2), induced BP (bars 1–3), PF (bars 4–6), and PV (bars 7–9) 
clinical blisters, respectively, 48 hours after pathogenic IgG administration. (E). ELISA revealed similar levels of serum pathogenic anti-mBP180 
(bars 1 and 2), anti-Dsg1 (bars 4 and 5), and anti-Dsg3 (bars 7 and 8) in mice injected with supernatants preabsorbed with buffer (bars 1, 4, and 7) 
and IgM (bars 2, 5, and 8). As expected, serum levels of pathogenic IgG were reduced in mice injected with supernatants preabsorbed with HDIG 
(bars 3, 6, and 9). n = 6. *P < 0.01.
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disease; 1+, mild erythematous reaction with no evidence of the epidermal 
detachment sign elicited by gentle friction of the mouse skin, which, when 
positive, produced fine, persistent wrinkling of the epidermis; 2+, intense 
erythema and epidermal detachment involving 10–50% of the epidermis in 
localized areas; and 3+, intense erythema with frank epidermal detachment 
involving more than 50% of the epidermis. The extent of cutaneous disease 
for IgG passive transfer PF and PV was scored as follows: –, no detectable skin 
blister when gentle friction of the mouse skin was introduced; 1+, epidermal 
wrinkling involving 10–30% of the epidermis in localized areas; 2+, epidermal 
wrinkling involving 30–60% of the epidermis in localized areas; 3+, epidermal 
wrinkling involving more than 60% of the epidermis in localized areas. Scores 
for all mice in each group were averaged and expressed as mean disease score 
± SEM. The animals were then sacrificed, and the following specimens were 
obtained: Skin sections were taken for light microscopy (H&E staining) and 
for direct IF analysis to detect bound pathogenic IgG in vivo. Sera of injected 
animals were obtained for ELISA to determine the circulating levels of anti-
mBP180, anti-Dsg1, and anti-Dsg3. Monospecific FITC-conjugated goat 
anti-human IgG and FITC-conjugated anti-rabbit IgG were obtained com-
mercially (Kirkegaard & Perry Laboratories Inc.).
HDIG treatment. Purified human IgG (GAMMAGARD) was obtained 
from Baxter International Inc. Fifty microliters of IVIG (0–5 mg in PBS/g 
body weight) was administrated i.p. 2 hours prior to pathogenic IgG injec-
tion. IgM (Sigma-Aldrich) at the same molar amount was used as a control 
for HDIG treatment. Mice with or without HDIG treatment were examined 
at 24 and 48 hours after pathogenic IgG injection as described above.
Quantification of skin site neutrophil accumulation in experimental BP. Tissue 
MPO activity in skin sites of the anti-mBP180–injected animals was assayed 
as described previously (19). A standard reference curve was first estab-
lished using known concentrations of purified MPO. The skin samples 
were extracted by homogenization in an extraction buffer containing 0.1 M 
Tris-Cl, pH 7.6, 0.1 M NaCl, 0.5% hexadecyl trimethylammoniumbromide. 
MPO activity in the supernatant fraction was measured by the change in 
OD at 460 nm resulting from decomposition of H2O2 in the presence of 
O-dianisidine. MPO content was expressed as units of MPO activity/mil-
ligram protein. Protein concentrations were determined by the Bio-Rad 
Laboratories Inc. dye binding assay using BSA as a standard.
Quantification of serum levels of rabbit anti-mBP180, human anti-Dsg1, and anti-
Dsg3 IgG. The concentration of serum rabbit anti-mBP180, human anti-
Dsg1, and human anti-Dsg3 IgG were measured by ELISA (66, 74). For rabbit 
anti-mBP180 ELISA, microtiter plates were coated with purified mBP180 
(1 µg/well), incubated with dilutions of serum, developed with HRP-conju-
gated goat antibodies specific for rabbit IgG F(ab′)2 (Cappel Laboratories), 
and read at OD492nm using an ELISA plate reader (Bio-Rad Laboratories Inc.). 
To quantify serum levels of human anti-Dsg1 and anti-Dsg3 IgG, Ni-NTA 
microplates (QIAGEN) were coated with purified human Dsg1 and Dsg3 pro-
teins (1.0 µg/well), incubated with dilutions of serum, developed with HRP-
conjugated mouse monoclonal antibody specific for human IgG (Zymed 
Laboratories Inc.), and read at 492 nm. For total rabbit IgG ELISA, microtiter 
plates were coated with 1 µg/well of polyclonal goat anti-rabbit IgG Fc anti-
body (Cappel Laboratories), incubated with dilutions of serum, developed 
with HRP-conjugated goat antibodies specific for rabbit IgG F(ab′)2 (Cappel 
Laboratories), and read at OD492nm using an ELISA plate reader (Bio-Rad 
Laboratories Inc.). IgG levels were expressed as relative OD reading (OD read-
ing of samples from mice injected with pathogenic IgG minus OD reading of 
samples from mice injected with control [buffer or control IgG]). The percent 
change in IgG levels was calculated by the following formula: [relative OD in 
IgM- or HDIG-treated mice / relative OD in mice injected with pathogenic 
IgG alone] × 100%. The detection limit for mBP180-, Dsg1-, Dsg3-specific IgG, 
and total rabbit IgG ELISAs were 0.044 ± 0.003, 0.102 ± 0.017, 0.130 ± 0.013, 
and 0.035 ± 0.003 OD reading units, respectively.
In vitro inhibition of pathogenic IgG binding to skin sections. Six-micrometer 
cryosections were cut from the back skin of neonatal WT and FcRn–/– mice. 
Pathogenic rabbit anti-mBP180 (1 mg/ml), human anti-Dsg1 (1 mg/ml), 
and human anti-Dsg3 (1 mg/ml) IgG were incubated with HDIG (25 mg/ml) 
in PBS for 1 hour at room temperature. After centrifugation, the superna-
tants were diluted 1:1,000, 1:2,000, 1:4,000, and 1:8,000 (detection limit 
for positive control) for anti-BP180 IgG with PBS and 1:200, 1:400, and 
1:800 (detection limit for positive control) for anti-Dsg1 and anti-Dsg3 
IgG with PBS-Ca2+ and then incubated with skin sections. Anti-BP180 
IgG binding to the basement membrane was detected with monospecific 
FITC-conjugated goat anti-rabbit IgG. Keratinocyte cell surface staining 
by anti-Dsg1 and anti-Dsg3 was detected with monospecific FITC-conju-
gated goat anti-human IgG.
Statistics. The data were expressed as mean ± SEM and were analyzed using 
the Student’s t test. A P value less than 0.05 was considered significant.
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Figure 8
Contribution of FcγRII to HDIG-induced degradation of pathogenic IgG. 
WT and FcγRII–/– mice were injected i.p. with pathogenic anti-BP180 
(25 µg/g body weight), anti-Dsg1 (40 µg/g body weight), or anti-Dsg3 
(50 µg/g body weight) IgG with buffer or HDIG (1 mg/g body weight) 
pretreatment. Mice were examined clinically, and the levels of circu-
lating pathogenic anti-mBP180, anti-Dsg1, and anti-Dsg3 antibodies 
were quantified 48 hours after IgG injection. HDIG treatment caused 
a similar degree of reduction in circulating pathogenic IgG levels and 
blocked clinical blister formation in both WT and FcγRII–/– mice. IgM 
control (6.47 mg/g body weight) showed results similar to those for 
buffer control (Table 2). n = 6 in each group.
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